Access Official Technical PDF

Share Summary:LinkedInEmail

DVDMS glioma therapy is being investigated as a way to activate a tumor-targeting sensitizer with either light or ultrasound. In a preclinical study, researchers evaluated sinoporphyrin sodium (DVDMS) in human glioma cells and a mouse xenograft model. Both photodynamic therapy (PDT) and sonodynamic therapy (SDT) inhibited cell proliferation and increased apoptosis when DVDMS was activated. The findings also point to reactive oxygen species (ROS) and changes in the PI3K/AKT/mTOR signaling pathway as possible contributors to these effects.

Why compare light- and ultrasound-activated therapy?

PDT uses a photosensitizer, light of an appropriate wavelength and oxygen to produce cell-damaging effects. Its use in tumors is limited in part by the depth to which light can penetrate tissue. SDT follows a related principle but uses ultrasound, rather than a laser, to activate a sensitizer. Ultrasound penetrates more deeply than light, making it a potential alternative for tumors where light delivery presents a challenge.

DVDMS is a water- and lipid-soluble sensitizer derived from Photofrin derivatives. The study examined its activation with both a 630-nanometer laser and 1-megahertz ultrasound. The central question was whether DVDMS-mediated PDT and SDT could affect glioma cells and tumors, and what biological changes might accompany any response.

DVDMS glioma therapy: findings in cells

In U-118 MG glioma cells, DVDMS uptake increased during incubation and was highest at four hours under the conditions tested. After this incubation period, cells received DVDMS alone, DVDMS plus laser, or DVDMS plus ultrasound. Researchers assessed cell proliferation and apoptosis using cell-based assays, staining and flow cytometry. A second glioma cell line, U-87 MG, was also included in proliferation testing.

Both DVDMS-PDT and DVDMS-SDT reduced proliferation and increased the proportion of apoptotic cells compared with the relevant untreated or sensitizer-only conditions. The apoptosis signal increased over time after treatment. By contrast, laser or ultrasound exposure alone did not produce the same reported therapeutic effect as combining an energy source with DVDMS.

The researchers also used N-acetyl-L-cysteine (NAC), a ROS scavenger, to probe the role of oxidative stress. NAC partly reduced treatment-associated apoptosis. It also partly reversed changes in selected proteins linked to proliferation and apoptosis. These results support a role for ROS in the cellular response, although they do not establish ROS as the only mechanism involved.

Results in a mouse xenograft model

The in vivo work used mice bearing subcutaneous U-118 MG tumors. DVDMS was administered intravenously, and PDT or SDT was performed 24 hours later. The treatment period involved two sessions, one week apart. The study compared control and single-component groups with low- and high-dose DVDMS-PDT and DVDMS-SDT groups.

After treatment, tumor size and weight were lower in the PDT and SDT groups than in the control group. The study did not find a significant tumor effect from applying laser, ultrasound or DVDMS individually. Fluorescence imaging showed lower DVDMS fluorescence in treated groups than in the DVDMS-only group, which the authors interpreted as consistent with photobleaching after activation. Tissue staining also indicated apoptosis and obstruction of blood vessels in treated tumors.

These findings are encouraging within the limits of the model. The tumors were implanted under the skin, not in the brain, so the experiment did not reproduce the intracranial environment or directly address delivery across the blood-brain barrier. The results therefore demonstrate preclinical activity in a xenograft setting, not established effectiveness in patients with glioma.

What the signaling results suggest

Protein analysis showed that DVDMS-mediated PDT and SDT reduced levels of proliferating cell nuclear antigen (PCNA), a marker associated with cell proliferation, and the anti-apoptotic protein Bcl-xL. Cleaved caspase-3, associated with apoptosis, increased. NAC partly reversed these changes, further supporting an involvement of ROS. Levels of Bax, another apoptosis-related protein measured in the study, did not change significantly across the three treatment conditions reported.

The researchers also examined phosphorylation in the PI3K/AKT/mTOR pathway, which is associated with cell growth and survival. PDT and SDT reduced phosphorylation of PI3K, AKT and mTOR, as well as several downstream proteins. Phosphorylation of 4EBP1 increased, a result the authors noted may require further investigation. These observations indicate that the pathway was affected, but do not by themselves establish exactly how those changes produce the observed tumor response.

Autophagy-related markers showed a more complex pattern. Both treatment approaches reduced p62 levels, while conversion of LC3-I to LC3-II increased with PDT but not in the same way with SDT. The study therefore suggests that PDT and SDT may differ in their effects on autophagy. The relationship between autophagy and treatment-induced cell death remains unresolved and warrants additional study.

Practical implications and next steps

The results position DVDMS as a sensitizer worth further investigation for both light- and ultrasound-activated approaches. SDT may be of particular interest where ultrasound penetration offers a practical advantage over light. PDT may have potential roles where light can be delivered, including settings involving surgical guidance, although the study did not test those applications directly.

Important questions remain before these findings can inform clinical care. The authors identify the need to evaluate treatment in an orthotopic brain-tumor model and to address the blood-brain barrier, which can limit drug delivery to the brain. Further work is also needed to clarify the roles of ROS, signaling changes and autophagy, and to determine how the two activation methods compare across relevant tumor models.

In summary, DVDMS activated by either laser or ultrasound inhibited glioma-cell growth and promoted apoptosis in the study’s cell and mouse models. The observed effects were associated with ROS-related changes and altered PI3K/AKT/mTOR signaling. For technical and clinical decision-makers, the key takeaway is that these are preclinical findings: they support continued investigation, while leaving delivery, mechanism and effectiveness in intracranial disease to be established.

Access Official Technical PDF

About The Author